<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988506</url>
  </required_header>
  <id_info>
    <org_study_id>P130101</org_study_id>
    <secondary_id>2013-001232-22</secondary_id>
    <nct_id>NCT01988506</nct_id>
  </id_info>
  <brief_title>Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases</brief_title>
  <acronym>TRANSREG</acronym>
  <official_title>Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in&#xD;
      a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in&#xD;
      which further therapeutic development will be performed. Extensive biological- and&#xD;
      immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct&#xD;
      processes responsible for the breakdown of immunological tolerance in these pathologies and&#xD;
      (ii) to discover potential biomarkers of the IL2 response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological&#xD;
      and clinical responses to the administration of low doses IL2 across 14 selected pathologies:&#xD;
      rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis,&#xD;
      Behcet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease, ulcerative&#xD;
      colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjögren, Systemic Sclerosis&#xD;
      and Idiopathic Thrombocytopenic Purpura. Methods: Each patient will receive 1MUI /day of IL2&#xD;
      from Day-1 to Day-5 (the induction period), and then every 2 weeks (except systemic lupus&#xD;
      erythematosus's patients will received every week) from Day-15 to Day-180 (the maintenance&#xD;
      period). Patients will thereafter be followed up for 12 months (Day-181-Day-540). For each&#xD;
      pathology, 6 patients will be included at Pitié-Salpêtrière, Cochin, Saint Antoine, Paul&#xD;
      Brousse and Henri Mondor hospitals in Paris and Créteil, France. An interim analysis will be&#xD;
      performed in each pathology group when the first six patients have received at least 3 months&#xD;
      of treatment. In those pathology groups in which a Treg response will be documented, six&#xD;
      additional patients will be included. In total, a minimum of 84 patients and up to 132&#xD;
      patients will be enrolled in this study. Primary efficacy endpoint is the Treg response at&#xD;
      Day-8 compared to baseline. Secondary efficacy endpoints are:- evolution of the Treg response&#xD;
      during the maintenance period,- the changes in markers of inflammation - the clinical&#xD;
      response, evaluated by means of global generic scales [Clinical Global Impression severity&#xD;
      scale (CGI-sev) and Clinical Global Impression efficacy index (CGI-eff)] as well as specific&#xD;
      clinical and biological evaluations for each disease, - the frequency of relapses, - the&#xD;
      assessment of quality of life (scale EuroQL-5). Expected Results: TRANSREG will define which&#xD;
      patients respond to IL2, whether per pathology or according to pre-treatment phenomics,&#xD;
      allowing to guide further clinical development of low dose IL2 in autoimmune and&#xD;
      auto-inflammatory diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day8</time_frame>
    <description>Change in Treg percentage (percentages of Tregs within the CD4+ lymphocytes) at Day-8 after administration of low-dose of IL2 compared to baseline (Day0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day 15, 29, 85, 183, 240, 360 and 540</time_frame>
    <description>Changes in Treg percentage at Day 15, 29, 85, 183, 240, 360 and 540 compared to baseline (Day0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation markers (CRP and CRP ultra sensible)</measure>
    <time_frame>Day 0, 1, 8, 15, 29, 85, 183, 240, 360 and 540</time_frame>
    <description>Changes in levels of inflammation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>markers of inflammatory anemia (Hemoglobin, serum iron level, transferrin) ferritin</measure>
    <time_frame>Day 0, 1, 8, 15, 29, 85, 183, 240, 360 and 540</time_frame>
    <description>Changes in levels of inflammation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>up to Day540</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-sev, CGI-activity and CGI-eff scales</measure>
    <time_frame>Day 85, 183, 240, 360 and 540</time_frame>
    <description>Change in the clinical global impression severity and efficacy scale (CGI-sev, CGI-act and CGI-eff scales) at Day 85, 183, 240, 360 and 540 compared to baseline (Day1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQL-5 scale</measure>
    <time_frame>Day 183</time_frame>
    <description>Change in the quality of life (EuroQL-5 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of clinical, biological or radiological criteria specific to each disease</measure>
    <time_frame>up to Day 540</time_frame>
    <description>Changes in disease-specific score and/or evolution of clinical, biological or radiological criteria specific to each disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>up to Day 540</time_frame>
    <description>Safety Assessment all along the observation period (Day-1 to Day-240): Safety assessment will include vital signs, adverse events and concomitant medications collection as well as biology during the 6 months of the treatment period; .In addition, the evolution of the disease will be followed up to 1 year after IL2- treatment stop.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Psoriasis</condition>
  <condition>Behcet's Disease</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Takayasu's Disease</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Sclerosing Cholangitis</condition>
  <condition>Gougerot-sjögren</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Interleukin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin 2, 1MUI.= Proleukin®, RhIL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin 2</intervention_name>
    <description>Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months</description>
    <arm_group_label>Interleukin 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 year&#xD;
&#xD;
          -  male or female&#xD;
&#xD;
          -  documented diagnosis of one AIID among the 14 diseases selected (following consensual&#xD;
             specific criteria)&#xD;
&#xD;
          -  stable or moderately active disease (except Lupus) under standard treatment (≥ 2&#xD;
             months) at the time of inclusion (except Sclerosing Cholangitis, Gougerot-sjögren,&#xD;
             Takayasu's Disease and Systemic Sclerosis)&#xD;
&#xD;
          -  normal thyroid function (with or without treatment)&#xD;
&#xD;
          -  effective contraception for more than two weeks at inclusion and negative beta HCG&#xD;
             test for women of childbearing potential,&#xD;
&#xD;
          -  affiliated to the social security system&#xD;
&#xD;
          -  written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known intolerance for IL2 (see SPC),&#xD;
&#xD;
          -  administration of a non-authorized treatment and/or IV bolus of corticosteroids in the&#xD;
             last 2 months,&#xD;
&#xD;
          -  vaccination with live attenuated virus in the months preceding the inclusion or&#xD;
             planned during the study&#xD;
&#xD;
          -  other severe or progressive autoimmune/inflammatory pathology,&#xD;
&#xD;
          -  low white blood cell count&lt;2000/mm3, lymphocytes &lt;600/mm3, platelets &lt;80 000/mm3,&#xD;
&#xD;
          -  heart failure (≥ grade III NYHA), renal insufficiency (Cockcroft&lt; 60ml/mn except&#xD;
             patients with lupus or Wegener's granulomatosis) or hepatic insufficiency&#xD;
             (transaminases&gt; 5N except for patients with autoimmune hepatitis), or lung failure,&#xD;
&#xD;
          -  significant abnormality in chest X-ray other than these linked to the diseases under&#xD;
             investigation&#xD;
&#xD;
          -  cancer or history of cancer cured for less than five years (except in situ carcinoma&#xD;
             of the cervix or basocellular carcinoma)&#xD;
&#xD;
          -  poor venous access not allowing repeated blood tests,&#xD;
&#xD;
          -  restrictive diet or parenteral nutrition,&#xD;
&#xD;
          -  surgery during the last 2 months or surgery planned during the study,&#xD;
&#xD;
          -  participation in other biomedical research in the last 3 months or planned during the&#xD;
             study.&#xD;
&#xD;
          -  pregnant or lactating women,&#xD;
&#xD;
          -  concomitant psychiatric disease or any other chronic illness or drug-abuse that could&#xD;
             interfere with the ability to comply with the protocol or to give informed consent,&#xD;
&#xD;
          -  positive HIV serology, active hepatitis B or EBV infection,&#xD;
&#xD;
          -  patients under a measure of legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David KLATZMANN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d' Hépato Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <state>Ile De France</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Mondor - Médecine Interne</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Médecine interne - Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de médecine vasculaire - HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL2,</keyword>
  <keyword>Interleukin 2,</keyword>
  <keyword>ILT101</keyword>
  <keyword>Proleukin®, RhIL-2</keyword>
  <keyword>Auto-immune disease</keyword>
  <keyword>Inflammatory disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Regulatory T cells,</keyword>
  <keyword>Treg</keyword>
  <keyword>Immunoregulation</keyword>
  <keyword>Immune tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

